Literature DB >> 3137618

A pharmacokinetic study of trifluoperazine in two ethnic populations.

K K Midha1, E M Hawes, J W Hubbard, E D Korchinski, G McKay.   

Abstract

The single dose pharmacokinetics of trifluoperazine (5 mg, Stelazine) were investigated in black (n = 25) and white (n = 32) healthy male subjects. Plasma samples were harvested over 24 h and analysed by a GLC-MS method. There were wide intersubject variations in all pharmacokinetic parameters examined, including Cmax, AUC, apparent oral volume of distribution at steady state, and elimination half-life. For each of these parameters the distribution was positively skewed in both blacks and whites and the geometric mean gave a better estimate of central tendency than the corresponding arithmetic mean. In all pharmacokinetic parameters examined there was no significant difference detected between black and white subjects or between smokers and non-smokers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137618     DOI: 10.1007/bf00181943

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Fluphenazine, trifluoperazine and perphenazine in Vacutainers.

Authors:  K K Midha; J K Cooper; Y D Lapierre; J W Hubbard
Journal:  Can Med Assoc J       Date:  1981-02-01       Impact factor: 8.262

Review 2.  Genetics of drug transformation.

Authors:  W Kalow
Journal:  Clin Biochem       Date:  1986-04       Impact factor: 3.281

3.  Plasma-trifluoperazine concentrations during high dose therapy.

Authors:  S H Curry; R B Stewart; P K Springer; J E Pope
Journal:  Lancet       Date:  1981-02-14       Impact factor: 79.321

4.  Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans.

Authors:  M Aravagiri; E M Hawes; K K Midha
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

5.  Kinetics of oral trifluoperazine disposition in man.

Authors:  K K Midha; E D Korchinski; R K Verbeeck; R M Roscoe; E M Hawes; J K Cooper; G McKay
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

6.  Plasma concentrations of trifluoperazine following single low doses.

Authors:  K K Midha; E M Hawes; G McKay; J W Hubbard; E D Korchinski; D L Keegan
Journal:  Can Med Assoc J       Date:  1983-08-15       Impact factor: 8.262

7.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Sensitive gas chromatographic determination of trifluoperazine in human plasma.

Authors:  T J Gillespie; I G Sipes
Journal:  J Chromatogr       Date:  1981-04-10

9.  Development and application of a specific radioimmunoassay for trifluoperazine N4'-oxide to a kinetic study in humans.

Authors:  M Aravagiri; E M Hawes; K K Midha
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

10.  Radioimmunoassay for trifluoperazine in human plasma.

Authors:  K K Midha; J W Hubbard; J K Cooper; E M Hawes; S Fournier; P Yeung
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

View more
  7 in total

1.  Ethnic differences in the neuroleptic treatment of schizophrenia.

Authors:  P Ruiz; R V Varner; D R Small; B A Johnson
Journal:  Psychiatr Q       Date:  1999

2.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

Review 3.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 4.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Authors:  K K Midha; J W Hubbard; S R Marder; B D Marshall; T Van Putten
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

Review 6.  Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

Authors:  G V Milton; M W Jann
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

7.  Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.

Authors:  E E J Kasteel; K Darney; N I Kramer; J L C M Dorne; L S Lautz
Journal:  Arch Toxicol       Date:  2020-05-15       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.